UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (date of earliest event reported): May 8, 2018
Zynex, Inc.
(Exact name of Registrant as specified in its charter)
| Nevada | 33-26787-D | 90-0275169 |
|
(State or other jurisdiction of incorporation) |
(Commission File Number) |
(I.R.S. Employer Identification No.) |
|
9555 Maroon Circle Englewood, Colorado |
80112 |
| (Address of principal executive offices) | (Zip Code) |
Registrant’s telephone number, including area code: (303) 703-4906
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b 2 of the Securities Exchange Act of 1934 (§240.12b 2 of this chapter).
Emerging Growth Company ¨
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to
Section 13(a) of the Exchange Act. ¨
| ITEM 2.02 | Results of Operations and Financial Condition |
On May 8, 2018, Zynex, Inc. issued a press release announcing its financial results for the first quarter ended March 31, 2018. The full text of the press release, together with the related unaudited financial and operating highlights, is furnished herewith as Exhibit 99.1.
| ITEM 9.01 | FINANCIAL STATEMENTS AND EXHIBITS |
d) Exhibits. The following exhibits are filed with this report.
| Exhibit No. | Description | |
| 99.1 | Press Release issued by Zynex, Inc. announcing the Company’s financial results for the first quarter ended March 31, 2018 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Zynex, Inc. | |||
| Date: | May 8, 2018 | By: | /s/ Daniel Moorhead |
| Daniel Moorhead | |||
| Chief Financial Officer |
Exhibit 99.1
Zynex Announces 2018 First Quarter Earnings
| · | Revenue grew 100% year over year to $6.9 million |
| · | Net income of $1.9 million increased 444% year over year; Diluted EPS $0.06 |
| · | Adjusted EBITDA of $2.0 million increased 257% year over year |
| · | Seventh consecutive quarter of positive net income, 82% gross margin and 28% operating margin |
ENGLEWOOD, CO – May 8, 2018 – Zynex, Inc. (OTCQB: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, stroke rehabilitation, cardiac monitoring and neurological diagnostics, today reported financial results for its first quarter ended March 31, 2018.
President and CEO Commentary:
Thomas Sandgaard, CEO said: “I am pleased to report revenue of $6.9 million in the first quarter with net income of $1.9 million or $0.06 per share. Adjusted EBITDA was $2.0 million and the quarterly revenue was twice the revenue of the first quarter of 2017. Revenue was less than the $8.1 million recorded in the fourth quarter of 2017 due to insurance company deductibles not being met early in the year, a seasonal trend we see every year in this industry. The investment in growing our sales force has led to device order growth of 36% compared to the first quarter of 2017 and 8% growth compared to the fourth quarter of 2017.
We currently estimate our second quarter revenue to range between $7.5 million and $8.0 million with Adjusted EBITDA between $2.5 million and $3.0 million. The revenue estimate is approximately 49% to 59% above last year’s second quarter and the Adjusted EBITDA estimate is 24% to 48% above last year.
We continue to advocate for pain patients not to become part of today’s opioid epidemic and for physicians to prescribe our NexWave technology as a first-line-of-defense in treating chronic and acute pain without side effects. I am dedicated to promote our technology in order to minimize addiction and other side effects from prescription opioids.”
First Quarter Financial Results Summary:
The Company reported net revenue of $6.9 million, a 100% increase over Q1-2017. First quarter revenue is historically our lowest of the year as it is affected by health insurance deductibles which have not been met.
Gross margins were 82% in the first quarter of 2018 compared to 73% last year. Net income grew 444% to $1.9 million in the first quarter of 2018, compared to $0.4 million last year.
Adjusted EBITDA grew 257% to $2.0 million in the first quarter of 2018 compared to $0.6 million last year.
The Company generated $1.0 million of cash from operations during the first quarter of 2018, an increase of 4,288% compared to $23,000 in 2017. As of March 31, 2018, the Company had working capital of $4.6 million compared to $4.4 million at December 31, 2017.
Webcast Details: Tuesday, May 8, 2018 at 9:00 a.m. MT – 11:00 a.m. ET
To register and participate in the webcast, interested parties should click on the following link or dial in approximately 10-15 minutes prior to the webcast:
https://www.webcaster4.com/Webcast/Page/1487/25740
| US PARTICIPANT DIAL IN (TOLL FREE): | 1-844-825-9790 |
| INTERNATIONAL DIAL IN: | 1-412-317-5170 |
| Canada Toll Free: | 1-855-669-9657 |
Non-GAAP Financial Measures
Zynex reports its financial results in accordance with accounting principles generally accepted in the U.S. (GAAP). In addition, the Company is providing in this news release financial information in the form of adjusted EBITDA (earnings before interest, taxes, depreciation, amortization and stock compensation). Management believes these non-GAAP financial measures are useful to investors and lenders in evaluating the overall financial health of the Company in that they allow for greater transparency of additional financial data routinely used by management to evaluate performance. Adjusted EBITDA can be useful for investors or lenders as an indicator of earnings available to service debt. Non-GAAP financial measures should not be considered in isolation from or as an alternative to the financial information prepared in accordance with GAAP.
About Zynex
Zynex, founded in 1996, markets and sells its own design of electrotherapy medical devices used for pain management and rehabilitation; and the company's proprietary NeuroMove device designed to help recovery of stroke and spinal cord injury patients. Zynex is also developing a new blood volume monitor for use in hospitals and surgery centers. For additional information, please visit: Zynex.com.
Safe Harbor Statement
Certain statements in this release are "forward-looking" and as such are subject to numerous risks and uncertainties. Actual results may vary significantly from the results expressed or implied in such statements. Factors that could cause actual results to materially differ from forward-looking statements include, but are not limited to, the need to obtain FDA clearance and CE marking of new products, the acceptance of new products as well as existing products by doctors and hospitals, larger competitors with greater financial resources, the need to keep pace with technological changes, our dependence on the reimbursement from insurance companies for products sold or rented to our customers, acceptance of our products by health insurance providers, our dependence on third party manufacturers to produce our goods on time and to our specifications, implementation of our sales strategy including a strong direct sales force our ability to up-list to a larger exchange and other risks described in our filings with the Securities and Exchange Commission including the "Risk Factors" section of our Annual Report on Form 10-K for the year ended December 31, 2017 as well as Forms 10-Q, 8-K and 8-K/A, press releases and the Company's website. Contact: Zynex, Inc. (303) 703-4906
Investor Relations Contact:
Amato And Partners, LLC
Investor Relations Counsel
admin@amatoandpartners.com
ZYNEX, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(in thousands, except share data)
(unaudited)
| March 31, | December 31, | |||||||
| 2018 | 2017 | |||||||
| ASSETS | ||||||||
| Current assets: | ||||||||
| Cash | $ | 4,366 | $ | 5,565 | ||||
| Accounts receivable, net | 2,668 | 2,185 | ||||||
| Inventory, net | 710 | 423 | ||||||
| Prepaid expenses | 615 | 198 | ||||||
| Total current assets | 8,359 | 8,371 | ||||||
| Property and equipment, net | 575 | 188 | ||||||
| Deposits | 375 | 370 | ||||||
| Total assets | $ | 9,309 | $ | 8,929 | ||||
| LIABILITIES AND STOCKHOLDERS' EQUITY | ||||||||
| Current liabilities: | ||||||||
| Current portion of unsecured subordinated promissory notes | $ | 7 | $ | 231 | ||||
| Current portion of capital leases | 93 | 123 | ||||||
| Accounts payable and accrued expenses | 2,112 | 2,243 | ||||||
| Accrued payroll and related taxes | 661 | 538 | ||||||
| Deferred insurance reimbursement | 880 | 880 | ||||||
| Total current liabilities | 3,753 | 4,015 | ||||||
| Long-term liabilities: | ||||||||
| Deferred rent | 329 | - | ||||||
| Warranty liability | 12 | 12 | ||||||
| Total liabilities | 4,094 | 4,027 | ||||||
| Stockholders' equity: | ||||||||
| Common stock | 33 | 33 | ||||||
| Additional paid-in capital | 7,761 | 7,612 | ||||||
| Treasury stock | (2,000 | ) | (243 | ) | ||||
| Retained deficit | (490 | ) | (2,411 | ) | ||||
| Total Zynex, Inc. stockholders' equity | 5,304 | 4,991 | ||||||
| Non-controlling interest | (89 | ) | (89 | ) | ||||
| Total stockholders' equity | 5,215 | 4,902 | ||||||
| Total liabilities and stockholders' equity | $ | 9,309 | $ | 8,929 | ||||
ZYNEX, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(in thousands, except per share data)
(unaudited)
| For the Three Months Ended March 31, | ||||||||
| 2018 | 2017 | |||||||
| NET REVENUE | ||||||||
| Devices | $ | 1,588 | $ | 1,384 | ||||
| Supplies | 5,288 | 2,052 | ||||||
| Total net revenue | 6,876 | 3,436 | ||||||
| COSTS OF REVENUE AND OPERATING EXPENSES | ||||||||
| Costs of revenue - device & supply | 1,236 | 923 | ||||||
| Selling, general and administrative expense | 3,685 | 2,030 | ||||||
| Total costs of revenue and operating expenses | 4,921 | 2,953 | ||||||
| Income from operations | 1,955 | 483 | ||||||
| Other expense | ||||||||
| Interest expense | (115 | ) | (121 | ) | ||||
| Other expense | (115 | ) | (121 | ) | ||||
| Income from operations before income taxes | 1,840 | 362 | ||||||
| Income tax expense (benefit) | (81 | ) | 9 | |||||
| Net Income | 1,921 | 353 | ||||||
| Plus: Net income (loss) - noncontrolling interest | - | - | ||||||
| Net income - attributable to Zynex, Inc. | $ | 1,921 | $ | 353 | ||||
| Net income per share attributable to Zynex, Inc.: | ||||||||
| Basic | $ | 0.06 | $ | 0.01 | ||||
| Diluted | $ | 0.06 | $ | 0.01 | ||||
| Weighted average basic shares outstanding | 32,601 | 31,418 | ||||||
| Weighted average diluted shares outstanding | 34,414 | 32,036 | ||||||
ZYNEX, INC.
Reconciliation of GAAP to Non-GAAP Measures
(in thousands)
(unaudited)
| For the Three Months Ended March 31, | ||||||||
| 2018 | 2017 | |||||||
| Adjusted EBITDA: | ||||||||
| Net income | $ | 1,921 | $ | 353 | ||||
| Depreciation and Amortization | 25 | 64 | ||||||
| Stock-based compensation expense | 63 | 24 | ||||||
| Interest expense and other, net | 115 | 121 | ||||||
| Income tax expense (benefit) | (81 | ) | 9 | |||||
| Adjusted EBITDA | $ | 2,043 | $ | 571 | ||||
| 30 | % | 17 | % | |||||